Drug application
RIVASTIGMINE (RIVASTIGMINE)
Drugs@FDA ANDA 204403 · ALVOGEN
Key facts
| Drug name | RIVASTIGMINE |
|---|---|
| Active ingredients | RIVASTIGMINE |
| Application type | ANDA |
| Application number | 204403 |
| Company | ALVOGEN |
| Dosage forms | FILM, EXTENDED RELEASE, TRANSDERMAL |
| Strength | 4.6MG/24HR |
| Marketing status | Discontinued |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Sep 3, 2015 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: